# Phase 2 Shigella Vaccine and Challenge

> **NCT04242264** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 69 (actual)

## Conditions studied

- Immunisation
- Shigella Infection

## Interventions

- **OTHER:** Placebo
- **BIOLOGICAL:** Shigella sonnei strain 53G
- **BIOLOGICAL:** WRSs2

## Key facts

- **NCT ID:** NCT04242264
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-12
- **Primary completion:** 2024-03-11
- **Final completion:** 2024-07-08
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04242264

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04242264, "Phase 2 Shigella Vaccine and Challenge". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04242264. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*